REGENXBIO INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.69 USD | -2.61% |
|
-12.93% | -12.59% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Calendar
2024-04-30
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
16.11
USD
Average target price
39.83
USD
Spread / Average Target
+147.26%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -12.59% | 790M | |
| -3.10% | 102B | |
| +2.11% | 96.07B | |
| -1.80% | 21.66B | |
| -17.75% | 20.77B | |
| -6.91% | 18.53B | |
| -42.00% | 16.91B | |
| -28.19% | 13.79B | |
| +0.18% | 13.33B | |
| +19.90% | 10.94B |
- Stock Market
- Equities
- RGNX Stock
- News REGENXBIO Inc.
- UBS Trims Price Target on REGENXBIO to $51 From $53, Reiterates Buy Rating
